A Multicenter, Single Arm, Open Label Phase II Clinical Study Evaluating the Long-term Efficacy and Safety of SHR-1918 in Homozygous Familial Hypercholesterolemia Patients
Latest Information Update: 01 Sep 2025
At a glance
- Drugs SHR-1918 (Primary)
- Indications Hyperlipoproteinaemia type II
- Focus Adverse reactions
- Sponsors Beijing Suncadia Pharmaceuticals
Most Recent Events
- 28 Aug 2025 New trial record